The prototypical ranitidine analog JWS-USC-75-IX improves information processing and cognitive function in animal models

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 3, 2011, Pages 751-766

  Terry Jr , Alvin V ^a   Buccafusco, Jerry J ^a,c   Herman, Elizabeth J ^a   Callahan, Patrick M ^a   Beck, Wayne D ^a   Warner, Samantha ^a   Vandenhuerk, Leah ^a   Bouchard, Kristy ^a   Schwarz, Gary M ^a   Gao, Jie ^b   Chapman, James M ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b University of South Carolina   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[[3 [[[2 [[(5 DIMETHYLAMINO METHYL) 2 FURANYL]METHYL]THIO]ETHYL]AMINO] 4 NITROPYRIDAZINE; ACETYLCHOLINESTERASE; CHOLINESTERASE; DONEPEZIL; GALANTAMINE; ION CHANNEL; NEUROTRANSMITTER RECEPTOR; NEUROTRANSMITTER TRANSPORTER; RANITIDINE DERIVATIVE; RIVASTIGMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION; BEHAVIOR; BINDING AFFINITY; CATALEPSY; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; IC 50; INFORMATION PROCESSING; LOCOMOTION; MALE; MEMORIAL PAIN ASSESSMENT CARD; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; REACTION TIME; ROTAROD TEST; STARTLE REFLEX;

ANIMALS; AVOIDANCE LEARNING; COGNITION; FEMALE; MACACA NEMESTRINA; MALE; MEMORY, SHORT-TERM; MODELS, ANIMAL; MOTOR ACTIVITY; RANITIDINE; RATS; RATS, WISTAR; REACTION TIME;

EID: 79951976804     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.175422     Document Type: Article

References (43)

1. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K, Flach K, Nagamoto H, Bickford P, Leonard S, et al. (1998) Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 24:189-202. (Pubitemid 28404980)
2. Akhtar M, Uma Devi P, Ali A, Pillai KK, and Vohora D (2006) Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice. Fundam Clin Pharmacol 20:373-378. (Pubitemid 44034327)
3. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, Gill R, Juszczak E, Yu LM, Jacoby R, et al. (2009) The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 8:151-157.
4. Ballmaier M, Casamenti F, Scali C, Mazzoncini R, Zoli M, Pepeu G, and Spano PF (2002) Rivastigmine antagonizes deficits in prepulse inhibition induced by selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis. Neuroscience 114:91-98. (Pubitemid 35247492)
5. Bürki HR (1979) Extrapyramidal side-effects. Pharmacol Ther B 5:525-534.
6. Collier TL, Waterhouse RN, and Kassiou M (2007) Imaging sigma receptors: applications in drug development. Current Pharmaceutical Design 13:51-72. (Pubitemid 46085300)
7. Ellman GL, Courtney KD, Andres V Jr, and Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity.Biochem Pharmacol 7:88-95.
8. Ennaceur A and Delacour J (1988) A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 31:47-59.
9. Espallergues J, Lapalud P, Christopoulos A, Avlani VA, Sexton PM, Vamvakides A, and Maurice T (2007) Involvement of the sigma1 (sigma1) receptor in the antiamnesic, but not antidepressant-like, effects of the aminotetrahydrofuran derivative ANAVEX1-41. Br J Pharmacol 152:267-279. (Pubitemid 47517609)
10. Eustace A, Coen R, Walsh C, Cunningham CJ, Walsh JB, Coakley D, and Lawlor BA (2002) A longitudinal evaluation of behavioural and psychological symptoms of probable Alzheimer's disease. Int J Geriatr Psychiatry 17:968-973. (Pubitemid 35189626)
11. Geyer MA and Ellenbroek B (2003) Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1071-1079. (Pubitemid 37464953)
12. Graham FK, Putnam LE, and Leavitt LA (1975) Lead-stimulation effects of human cardiac orienting and blink reflexes. J Exp Psychol Hum Percept Perform 104:175-182.
13. Gwee MC and Cheah LS (1986) Actions of cimetidine and ranitidine at some cholinergic sites: implications in toxicology and anesthesia. Life Sci 39:383-388. (Pubitemid 16070681)
14. Hohnadel E, Bouchard K, and Terry AV Jr (2007) Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats. Neuropharmacology 52:542-551. (Pubitemid 46123371)
15. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
16. Jones CK and Shannon HE (2000) Muscarinic cholinergic modulation of prepulse inhibition of the acoustic startle reflex. J Pharmacol Exp Ther 294:1017-1023. (Pubitemid 30666854)
17. Jones CK, Eberle EL, Shaw DB, McKinzie DL, and Shannon HE (2005) Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats. J Pharmacol Exp Ther 312:1055-1063.
18. Kapur S and Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27:1081-1090. (Pubitemid 37464954)
19. Lai MK, Lai OF, Keene J, Esiri MM, Francis PT, Hope T, and Chen CP (2001) Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex. Neurology 57:805-811. (Pubitemid 32845499)
20. Mansbach RS, Geyer MA, and Braff DL (1988) Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology 94:507-514. (Pubitemid 18087401)
21. Mansbach RS and Geyer MA (1989) Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2:299-308. (Pubitemid 20025258)
22. Mash DC, Flynn DD, and Potter LT (1985) Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 228:1115-1117. (Pubitemid 15227377)
23. Michal P, Lysíková M, and Tucek S (2001) Dual effects of muscarinic M(2) acetylcholine receptors on the synthesis of cyclic AMP in CHO cells: dependence on time, receptor density and receptor agonists. Br J Pharmacol 132:1217-1228. (Pubitemid 32234705)
24. Middlemore-Risher ML, Buccafusco JJ, and Terry AV Jr (2010) Repeated exposures to low-level chlorpyrifos results in impairments in sustained attention and increased impulsivity in rats. Neurotoxicol Teratol 32:415-424.
25. Minger SL, Esiri MM, McDonald B, Keene J, Carter J, Hope T, and Francis PT (2000) Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology 55:1460-1467.
26. Miyamoto S, Duncan GE, Marx CE, and Lieberman JA (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79-104. (Pubitemid 40139590)
27. Paule MG, Bushnell PJ, Maurissen JP, Wenger GR, Buccafusco JJ, Chelonis JJ, and Elliott R (1998) Symposium overview: the use of delayed matching-to-sample procedures in studies of short-term memory in animals and humans. Neurotoxicol Teratol 20:493-502. (Pubitemid 28511113)
28. Quirion R (1993) Cholinergic markers in Alzheimer disease and the autoregulation of acetylcholine release. J Psychiatry Neurosci 18:226-234.
29. Robbins TW (2002) The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology 163:362-380.
30. Sanberg PR, Bunsey MD, Giordano M, and Norman AB (1988) The catalepsy test: its ups and downs. Behav Neurosci 102:748-759.
31. Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, et al. (2008) Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 325:681-690. (Pubitemid 351574819)
32. Schott Y, Decker M, Rommelspacher H, and Lehmann J (2006) 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett 16:5840-5843. (Pubitemid 44488737)
33. Squire LR, Stark CE, and Clark RE (2004) The medial temporal lobe. Annu Rev Neurosci 27:279-306. (Pubitemid 39050405)
34. Stanhope KJ, Mirza NR, Bickerdike MJ, Bright JL, Harrington NR, Hesselink MB, Kennett GA, Lightowler S, Sheardown MJ, Syed R, et al. (2001) The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J Pharmacol Exp Ther 299:782-792.
35. Terry AV Jr, Buccafusco JJ, and Bartoszyk GD (2005) Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys. Psychopharmacology 179:725-732. (Pubitemid 40767893)
36. Terry AV Jr, Gattu M, Buccafusco JJ, Sowell JW, and Kosh JW (1999) Ranitidine analog, JWS USC 75IX, enhances memory-related task performance in rats. Drug Dev Res 47:97-106. (Pubitemid 29350663)
37. Terry AV Jr, Gearhart DA, Warner SE, Zhang G, Bartlett MG, Middlemore ML, Beck WD Jr, Mahadik SP, and Waller JL (2007) Oral haloperidol or risperidone treatment in rats: temporal effects on nerve growth factor receptors, cholinergic neurons, and memory performance. Neuroscience 146:1316-1332. (Pubitemid 46711147)
38. United Nations. (2007) World Population Ageing, United Nations, New York.
39. U.S. CDC (2003) From the Centers for Disease Control and Prevention. Public health and aging: trends in aging-United States and worldwide. JAMA 289:1371-1373.
40. Valli MJ, Tang Y, Kosh JW, Chapman JM Jr, and Sowell JW Sr (1992) Synthesis and cholinergic properties of N-aryl-2-[[[5-[(dimethylamino)methyl]-2- furanyl]methyl-]thio]ethylamino analogs of ranitidine. J Med Chem 35:3141-3147.
41. Wadenberg ML and Hicks PB (1999) The conditioned avoidance response test reevaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 23:851-862.
42. Youdim MB and Buccafusco JJ (2005) Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 26:27-35. (Pubitemid 40052707)
43. Zhang J, Zhu D, Sheng R, Wu H, Hu Y, Wang F, Cai T, Yang B, and He Q (2009) BZYX, a novel acetylcholinesterase inhibitor, significantly improved chemicals-induced learning and memory impairments on rodents and protected PC12 cells from apoptosis induced by hydrogen peroxide. Eur J Pharmacol 613:1-9.